VENATORX PHARMACEUTICALS INC — Department of Health and Human Services SBIR Phase II: NIAID
VENATORX PHARMACEUTICALS INC — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $3,000,000, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $3,000,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NIAID
- Solicitation
- PA17-302
- NAICS
- —
- Place of performance
- PA
- Period
- 2018-02-07 → 2021-01-31
Description
Project Summary This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA, Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired with a proprietary in-house β-lactamase inhibitor VNRX-5133 (BLI) to protect against resistance by Ambler Class A, B and D carbapenemase-producing Gram negatives. In parallel, a discovery effort will be executed to identify a fast follower and/or chemically-diverse back-up UBSC that could be advanced into IND-enabling studies if required. Ultimately, it is envisioned that this new combination product will provide a unique clinical option for empiric therapy of multi-drug resistant polymicrobial infections in the hospital general ward and ICU, and as a second line therapy for susceptible organisms.Project Narrative We are developing a Preclinical Candidate from a new class of ultra-broad spectrum carbapenems with activity that extends to MRSA, Enterobacteriaceae and Pseudomonas aeruginosa. The compound will be paired with a proprietary β-lactamase inhibitor with activity that extends to all Ambler classes of carbapenemases. This combination promises to be a powerful new single-treatment option against problematic, multi-drug resistant pathogens.